New effective treatment options reinforce disease awareness: the case of transthyretin cardiac amyloidosis

Eur J Heart Fail. 2021 Feb;23(2):290-292. doi: 10.1002/ejhf.2111. Epub 2021 Feb 11.

Authors

Stefano Perlini^{1

2}, Roberta Mussinelli², Francesco Salinaro¹

Affiliations

¹ Emergency Medicine, Vascular and Metabolic Disease Unit, Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.
² Amyloidosis Research and Treatment Center, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.

PMID: 33527646
DOI: 10.1002/ejhf.2111

No abstract available

Publication types

Editorial
Comment

MeSH terms

Amyloid Neuropathies, Familial*
Heart Failure*
Humans
Prealbumin
Treatment Outcome

Substances

Prealbumin